Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2010 - 2026)

Pacific Biosciences Of California's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $782.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 9.11% year-over-year to $782.4 million; the TTM figure through Mar 2026 stood at $3.2 billion (down 37.11% YoY), while the FY2025 annual figure was $784.1 million, down 37.79% from the prior year.
• Liabilities and Shareholders Equity was $782.4 million for Q1 2026 at Pacific Biosciences Of California, roughly flat from $784.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.9 billion in Q1 2022 to a low of $782.4 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.5 billion across 5 years, with a median of $1.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 54.58% in 2022, then plunged 48.45% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.8 billion in 2022, then retreated by 1.19% to $1.7 billion in 2023, then fell by 27.81% to $1.3 billion in 2024, then slumped by 37.79% to $784.1 million in 2025, then dropped by 0.22% to $782.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $782.4 million (Q1 2026), $784.1 million (Q4 2025), and $803.2 million (Q3 2025), per Business Quant data.